In the Media

Global Roundup: BioMed X, Merck KGaA Expand Oncology Collaboration

BioSpace

Germany-based BioMed X Institute expanded its collaboration with Merck KGaA, Darmstadt, Germany to include a total of eight research programs in the field of DNA damage response and RNA splicing.

BioMed X expands research partnership with Merck KGaA

Pharmaceutical Commerce

BioMed X, an independent research institute, revealed the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will dive into the role of extrachromosomal DNA in cancer and it will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA splicing.

BioMed X Expands Collaboration with Merck

Contract Pharma

BioMed X, an independent research institute, has initiated its eighth joint research program with Merck KGaA, Darmstadt, Germany.

BioMed X and Merck launch new Oncology research programme

Pharmafile

BioMed X and Merck have launched a new joint research programme in oncology.

Merck KGaA and BioMed X launch new joint cancer research programme

PharmaTimes online

German pharma company Merck KGaA has announced a new partnership with BioMed X, an independent research institute located at the University of Heidelberg in Germany, in the area of oncology.

BioMed X and Merck launch oncology research programme

Manufacturing Chemist

The key aim of the project will be to generate a comprehensive atlas of extrachromosomal DNA in human cancer tissues.

BioMed X and Merck KGaA, Darmstadt, Germany launch new research program in oncology

1st Oncology

On July 5, 2021 BioMed X, a leading independent research institute, reported the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany.

BioMed X and Merck Extend Collaboration to Advance Oncology an Autoimmunity Research

Pharma Tech Outlook

Merck will support up to six different research groups at Heidelberg’s BioMed X Institute over the next six years.

Merck extends oncology and autoimmunity collaboration with BioMed X

Pharma Times

Merck has extended its existing collaboration with BioMed X, an independent research institute located at the University of Heidelberg in Germany, to continue research in the areas of oncology and autoimmunity.

Merck, BioMed X extend collaboration in oncology, autoimmunity

Merck has extended its collaboration with German company BioMed X and will start six additional research projects at the BioMed X Institute.

BioMedX Extends Collaboration with Merck

BioMed X, an independent biomedical research institute, has extended its ongoing collaboration with Merck.

The BioMedX Institute: a new research model at the interface between industry and academia

Chemicals Knowledge Hub

BioMed X is a new collaborative model between academia and industry developing innovative products in the fields of biomedicine, molecular biology, cell biology and diagnostics.

Studying Depression at a Molecular Level

Psychiatric Times

How do defective neuro-glia interactions contribute to depression? A recent study suggests that alterations in astrocyte metabolism is a major hallmark of depression. In this Mental Health Minute, Michal Slezak, PhD, explains how he and other researchers used state-of-the-art imaging techniques and genetic approaches to identify molecular processes impaired in depression.

Digitization and AI at the Forefront

STARTUPCITY

“In the midst of every crisis, lies great opportunity.” Regarding the most important trends in biomedical research for 2021, this quote by Albert Einstein seems more topical than ever before.

Crossing the Border

the Medicine Maker

How to get macromolecules across the intestinal epithelial barrier

J&J taps BioMed X for crowdsourced oral biologics delivery push

FiercePharma

Johnson & Johnson has teamed up with BioMed X Institute to advance oral delivery of monoclonal antibodies and other biologics. The initiative will support the work of a small team that will work to identify ways to get large molecules across the intestinal epithelial barrier.

BioMed X begins research project for oral therapeutics delivery

manufacturing Chemist

The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation.

El Instituto BioMed X inicia un nuevo proyecto de investigación sobre administración de fármacos en colaboración con Janssen

FarmaIndustrial

El instituto de investigación independiente alemán BioMed X anuncia su nuevo proyecto de investigación con Janssen Research & Development, una de las compañías farmacéuticas Janssen de Johnson & Johnson, que se esforzará por descubrir nuevos mecanismos de transporte en el tracto intestinal humano que podrían utilizarse para la administración oral de diversas modalidades terapéuticas.

BioMed X, Janssen Enter Oral Drug Delivery Alliance

ContractPharma

Aims to discover novel transport mechanisms which could be utilized for oral delivery of therapeutic modalities.

BioMed X Launches Drug Delivery Research Project with Janssen

BioPharm International

The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.

Crowdsourcing and open innovation in drug discovery: recent contributions and future directions

Drug Discovery Today

The past decade has seen significant growth in the use of ‘crowdsourcing’ and open innovation approaches to engage ‘citizen scientists’ to perform novel scientific research. Here, we quantify and summarize the current state of adoption of open innovation by major pharmaceutical companies.